Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Gene Cradle logo — Developing gene therapy drugs to treat rare genetic diseases...

Gene Cradle

Developing gene therapy drugs to treat rare genetic diseases and chronic conditions

Founded 2018 Series B Total: $100.00M

General Information

Company Name Gene Cradle
Founded Year 2018
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Gene Cradle. To contact Gene Cradle, visit bj-genecradle.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Gene Cradle

> is a genetic company founded in >, dedicated to the development of gene therapy drugs for treating rare genetic diseases and chronic conditions. The company's mission, as encapsulated in its slogan "Developing gene therapy drugs to treat rare genetic diseases and chronic conditions," underscores a commitment to addressing pressing medical needs through innovative genetic advancements. Their most recent investment, a > on >, was facilitated by >. These investments are indicative of the confidence and support garnered by >, signaling a recognition of its potential impact on the healthcare landscape. With a focus on pioneering solutions for under-addressed medical conditions, > stands poised to make meaningful contributions to the field of genetic medicine.

Taxonomy: gene therapy, rare genetic diseases, chronic diseases, genetic company, drug development, gene editing, precision medicine, medical research, genomics, innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B Undisclosed 2
CASH Capital, BioVenture
07 Aug 2023
Series B CNY100.00M 2
Oriental Fortune Capital
Oriental Fortune Capital, Qiandao Fund
16 Jun 2023

Gene Cradle Alternatives & Competitors

View All Alternatives
Gene Cradle vs
Locanabio, Inc.
Locanabio, Inc. United States

Creating RNA-targeting gene therapies to treat devastating diseases

Series B
7 employees
Biotechnology, Health Care
Gene Cradle vs
GenEditBio Limited
GenEditBio Limited Hong Kong S.a.r.

A biotech startup company aiming to provide potentially curative gene editing-based solutions for ge...

Seed
18 employees
Biotechnology
Gene Cradle vs
Gene Vector
Gene Vector

Pioneering the future of AAV gene therapy for ophthalmic, neuromuscular, genetic, and metabolic dise...

Series A
Biotechnology
View all alternatives

FAQ About Gene Cradle

Developing gene therapy drugs to treat rare genetic diseases and chronic conditions
Gene Cradle was founded in 2018.
Gene Cradle has completed 2 funding rounds, raising a total of $100.00M. The latest funding stage is Series B.
Top alternatives and competitors to Gene Cradle include Locanabio, Inc., GenEditBio Limited, Gene Vector, Autifony Therapeutics, Homology Medicines. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Gene Cradle and Locanabio, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Gene Cradle, https://bouncewatch.com/company/gene-cradle, updated 27 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes